Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7409083 | 0.87 | F10 (0.37) | F10DGAT1F2 | |
| Trifluoroacetic Acid SCHEMBL7536994 | 0.85 | F10 (0.39) | F10DGAT1HCRTR1F2 | |
| Trifluoroacetic Acid SCHEMBL7537068 | 0.85 | F10 (0.37) | F10DGAT1F2 | |
| Trifluoroacetic Acid SCHEMBL7537062 | 0.85 | F10 (0.37) | F10DGAT1F2 | |
| Trifluoroacetic Acid SCHEMBL7543773 | 0.82 | F10 (0.38) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL7536899 | 0.81 | F10 (0.41) | F10DGAT1 | |
| Trifluoroacetic Acid SCHEMBL7540671 | 0.81 | F10 (0.41) | F10DGAT1 | |
| Trifluoroacetic Acid SCHEMBL7598138 | 0.78 | F10 (0.54) | F10DGAT1 | |
| Trifluoroacetic Acid SCHEMBL7375811 | 0.77 | F10 (0.30) | F10 | |
| Trifluoroacetic Acid SCHEMBL7540711 | 0.76 | F10 (0.42) | F10DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | claimed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | F10 20/4885DGAT1 3918/4885HCRTR1 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.